LY2784544 is primarily used in research settings to study its potential as a therapeutic agent. It functions as a JAK2 inhibitor, making it particularly relevant in the investigation of myeloproliferative disorders, such as polycythemia vera, essential thrombocythemia, and myelofibrosis. By targeting the JAK2 pathway, it helps researchers understand the mechanisms of abnormal cell proliferation and evaluate its efficacy in reducing disease symptoms. Additionally, it serves as a tool in preclinical studies to explore its impact on other conditions linked to JAK2 mutations or dysregulation. Its application extends to the development of targeted therapies for cancers and inflammatory diseases where JAK2 signaling plays a critical role.